Novartis competitorsClear all

Novartis's top competitors include Bausch + Lomb, Immunomedics, Gilead Sciences, Sanofi, AstraZeneca, Johnson & Johnson, Bayer and Pfizer.
Novartis
Novartis
Novartis is a company that researches, develops, manufactures, and markets healthcare products.
Bausch + Lomb
Bausch + Lomb
Bausch + Lomb is a company that develops, manufactures, and markets healthcare products.
Immunomedics
Immunomedics
Immunomedics is a developer of monoclonal antibody-based products for the targeted treatment of cancer.
Gilead Sciences
Gilead Sciences
Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines.
Sanofi
Sanofi
Sanofi is a global healthcare company engaged in the research, development, manufacture, and marketing of therapeutic solutions.
AstraZeneca
AstraZeneca
AstraZeneca is a global science-led biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines.
Johnson & Johnson
Johnson & Johnson
Johnson & Johnson is a global holding company that engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Bayer
Bayer
Bayer is a global life science company specializing in healthcare and nutrition.
Pfizer
Pfizer
Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products.
Founding Date
Founding Date
1996
Founding Date
1853
Founding Date
1982
Founding Date
1987
Founding Date
2004
Founding Date
1999
Founding Date
1886
Founding Date
1863
Founding Date
1849
Type
Type
Public
Type
Subsidiary
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Basel, CH HQ
Tirana, AL
Bir Mourad Raïs, DZ
Duc, AR
Macquarie Park, AU
Wien, AT
Baku, AZ
see more
Locations
Bridgewater Township, US HQ
Buenos Aires, AR
Chatswood, AU
Wien, AT
Mechelen, BE
Vaughan, CA
Beijing, CN
see more
Locations
Morris Plains, US HQ
Rödermark, DE
Locations
Foster City, US HQ
Abb, AR
Melbourne, AU
Wien, AT
Machelen, BE
São Paulo, BR
Edmonton, CA
see more
Locations
Paris, FR HQ
Macquarie Park, AU
Wien, AT
Dhaka, BD
Brussel, BE
Geel, BE
Zaventem, BE
see more
Locations
Cambridge, GB HQ
Alger, DZ
Buenos Aires, AR
Haedo, AR
Macquarie Park, AU
Macquarie Park, AU
North Ryde, AU
see more
Locations
New Brunswick, US HQ
Buenos Aires, AR
Chippendale, AU
Wien, AT
Minsk, BY
Beerse, BE
Brussel, BE
see more
Locations
Leverkusen, DE HQ
Dely Ibrahim, DZ
Luanda, AO
Munro, AR
Pymble, AU
Wien, AT
Dhaka, BD
see more
Locations
New York, US HQ
Buenos Aires, AR
Villa Adelina, AR
Bentley, AU
Melbourne, AU
Mulgrave, AU
Sydney, AU
see more
Employees
Employees
105,7942% increase
Employees
6,611
Employees
3666% increase
Employees
11,8007% increase
Employees
100,4094% decrease
Employees
70,6009% increase
Employees
132,2002% decrease
Employees
101,1683% decrease
Employees
88,3004% decrease
Valuation ($)
Valuation ($)
N/A
Valuation ($)
N/A
Valuation ($)
20.3 b
Valuation ($)
82.8 b
Valuation ($)
130.6 b
Valuation ($)
140.1 b
Valuation ($)
435 b
Valuation ($)
63.8 b
Valuation ($)
222.2 b
Twitter followers
Twitter followers
292.1 k
Twitter followers
17.6 k
Twitter followers
608
Twitter followers
67.6 k
Twitter followers
140.9 k
Twitter followers
267.8 k
Twitter followers
230.3 k
Twitter followers
179.2 k
Twitter followers
25.3 k
Number of tweets (last 30 days)
Number of tweets (last 30 days)
21
Number of tweets (last 30 days)
16
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
14
Number of tweets (last 30 days)
42
Number of tweets (last 30 days)
39
Number of tweets (last 30 days)
67
Number of tweets (last 30 days)
183
Number of tweets (last 30 days)
7
Average likes per tweet (last 30 days)
Average likes per tweet (last 30 days)
8
Average likes per tweet (last 30 days)
1
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
91.8
Average likes per tweet (last 30 days)
24.8
Average likes per tweet (last 30 days)
58.8
Average likes per tweet (last 30 days)
13.2
Average likes per tweet (last 30 days)
3.4
Average likes per tweet (last 30 days)
11.1
Percentage of tweets with engagement (last 30 days)
Percentage of tweets with engagement (last 30 days)
57.14%
Percentage of tweets with engagement (last 30 days)
37.5%
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
92.31%
Percentage of tweets with engagement (last 30 days)
49.25%
Percentage of tweets with engagement (last 30 days)
43.72%
Percentage of tweets with engagement (last 30 days)
100%
Alexa Website Rank
Alexa Website Rank
88970
Alexa Website Rank
255681
Alexa Website Rank
282560
Alexa Website Rank
112610
Alexa Website Rank
123373
Alexa Website Rank
57766
Alexa Website Rank
19571
Alexa Website Rank
85997
Alexa Website Rank
28407
Employee Rating
Employee Rating
4.2
Employee Rating
N/A
Employee Rating
3.2
Employee Rating
3.8
Employee Rating
3.3
Employee Rating
4.2
Employee Rating
4.2
Employee Rating
N/A
Employee Rating
4.2

Financial

Revenue (est.)
Revenue (est.)
$48.7b (FY, 2020)
Revenue (est.)
N/A
Revenue (est.)
$295k (FY, 2019)
Revenue (est.)
$24.7b (FY, 2020)
Revenue (est.)
(€926m) (FY, 2020)
Revenue (est.)
$24.4b (FY, 2019)
Revenue (est.)
$82.1b (FY, 2019)
Revenue (est.)
€43.5b (FY, 2019)
Revenue (est.)
$41.9b (FY, 2020)
Cost of goods
Cost of goods
$15.1b (FY, 2020)
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
$4.6b (FY, 2020)
Cost of goods
€12.2b (FY, 2020)
Cost of goods
$4.9b (FY, 2019)
Cost of goods
$27.6b (FY, 2019)
Cost of goods
€17.5b (FY, 2019)
Cost of goods
$8.7b (FY, 2020)
Gross profit
Gross profit
$33.5b (FY, 2020)
Gross profit
N/A
Gross profit
$295k (FY, 2019)
Gross profit
$20.1b (FY, 2020)
Gross profit
(€13.1b) (FY, 2020)
Gross profit
$19.5b (FY, 2019)
Gross profit
$54.5b (FY, 2019)
Gross profit
€26.1b (FY, 2019)
Gross profit
$33.2b (FY, 2020)
Net income
Net income
$8.1b (FY, 2020)
Net income
N/A
Net income
($357.3m) (FY, 2019)
Net income
$89m (FY, 2020)
Net income
€12.4b (FY, 2020)
Net income
$1.2b (FY, 2019)
Net income
$15.1b (FY, 2019)
Net income
€2.4b (FY, 2019)
Net income
$9.7b (FY, 2020)

Operating

Approval Phase Products
Approval Phase Products
N/A
Approval Phase Products
N/A
Approval Phase Products
1 (FY, 2019)
Approval Phase Products
N/A
Approval Phase Products
N/A
Approval Phase Products
N/A
Approval Phase Products
N/A
Approval Phase Products
2 (Jan, 2020)
Approval Phase Products
N/A
Countries
Countries
N/A
Countries
100 (Nov, 2020)
Countries
N/A
Countries
35 (FY, 2019)
Countries
N/A
Countries
100 (FY, 2020)
Countries
60 (FY, 2018)
Countries
153 (FY, 2018)
Countries
125 (FY, 2019)
Patent Applications (US)
Patent Applications (US)
N/A
Patent Applications (US)
N/A
Patent Applications (US)
275 (Sep, 2020)
Patent Applications (US)
394 (Dec, 2020)
Patent Applications (US)
N/A
Patent Applications (US)
N/A
Patent Applications (US)
N/A
Patent Applications (US)
N/A
Patent Applications (US)
N/A
Patents (US)
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
390 (Sep, 2020)
Patents (US)
650 (Dec, 2020)
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
N/A
Phase I Trials Products
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
2 (FY, 2019)
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
26 (FY, 2019)
Phase I Trials Products (Oncology)
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
7 (FY, 2019)
Phase I Trials Products (Oncology)
12 (FY, 2020)
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase II Trials Products
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
4 (FY, 2019)
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
12 (Jan, 2020)
Phase II Trials Products
37 (FY, 2019)
Phase II Trials Products (Oncology)
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
2 (FY, 2019)
Phase II Trials Products (Oncology)
6 (FY, 2020)
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase III Trials Products
Phase III Trials Products
44 (Q4, 2020)
Phase III Trials Products
N/A
Phase III Trials Products
4 (FY, 2019)
Phase III Trials Products
27 (FY, 2019)
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
9 (Jan, 2020)
Phase III Trials Products
23 (FY, 2019)
Phase III Trials Products (Oncology)
Phase III Trials Products (Oncology)
22 (Q4, 2020)
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
1 (FY, 2019)
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Projects in R&D Pipeline
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
91 (FY, 2019)
Projects in R&D Pipeline
171 (FY, 2020)
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A
Properties
Properties
N/A
Properties
N/A
Properties
2 (FY, 2019)
Properties
N/A
Properties
N/A
Properties
N/A
Properties
N/A
Properties
N/A
Properties
453 (FY, 2019)
Registration Phase Products
Registration Phase Products
5 (Q4, 2020)
Registration Phase Products
N/A
Registration Phase Products
N/A
Registration Phase Products
N/A
Registration Phase Products
N/A
Registration Phase Products
N/A
Registration Phase Products
N/A
Registration Phase Products
N/A
Registration Phase Products
9 (FY, 2019)
Suppliers
Suppliers
N/A
Suppliers
N/A
Suppliers
N/A
Suppliers
N/A
Suppliers
68 k (FY, 2019)
Suppliers
N/A
Suppliers
3.5 k (Jun, 2018)
Suppliers
86.4 k (FY, 2019)
Suppliers
N/A

Funding

Total funding raised
Total funding raised
$ 6.5m
Total funding raised
N/A
Total funding raised
$ 30m
Total funding raised
N/A
Total funding raised
$ 310m
Total funding raised
$ 1b
Total funding raised
N/A
Total funding raised
$ 3.5b
Total funding raised
N/A
For sources of this data, please see the company profile

View company profiles

Bausch + Lomb
HQ
Bridgewater Township, US

Bausch + Lomb is a company that develops, manufactures, and markets healthcare products.

View company
Immunomedics
HQ
Morris Plains, US
Employees
366↑ 6% increase

Immunomedics is a developer of monoclonal antibody-based products for the targeted treatment of cancer.

View company
Gilead Sciences
HQ
Foster City, US
Employees
11,800↑ 7% increase

Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines.

View company
Sanofi
HQ
Paris, FR
Employees
100,409↓ 4% decrease

Sanofi is a global healthcare company engaged in the research, development, manufacture, and marketing of therapeutic solutions.

View company